Nabriva to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
September 06 2016 - 7:00AM
Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage
biopharmaceutical company engaged in the research and development
of novel anti-infective agents to treat serious infections, with a
focus on the pleuromutilin class of antibiotics, today announced
that Dr. Colin Broom, Nabriva’s Chief Executive Officer, will
present at the Rodman & Renshaw 18th Annual Global Investment
Conference on Monday, September 12, 2016 at 10:25a.m. Eastern Time
in New York, NY. Dr. Broom will provide a Nabriva overview
and business update.
The presentation will be webcast live and may be accessed by
visiting the "Investors" section of Nabriva’s web site under the
"Events and Presentations" tab at http://investors.nabriva.com/. A
replay the webcast will be available for 90 days.
About Nabriva Therapeutics AG
Nabriva Therapeutics is a clinical stage biopharmaceutical
company engaged in the research and development of novel
anti-infective agents to treat serious bacterial infections, with a
focus on the pleuromutilin class of antibiotics. Nabriva's
medicinal chemistry expertise has enabled targeted discovery of
novel pleuromutilins, including both intravenous and oral
formulations of its lead product candidate. Nabriva's lead
pleuromutilin product candidate, lefamulin, is being developed to
be the first systemically available pleuromutilin for human use and
is the first new class of antibiotic to reach late stage clinical
development for community-acquired bacterial pneumonia (CABP) in
over a decade. Nabriva believes lefamulin is well positioned for
use as a first-line empiric monotherapy for the treatment of
moderate to severe CABP due to its novel mechanism of action,
targeted spectrum of activity, resistance profile, achievement of
substantial drug concentration in lung tissue and fluid, oral and
IV formulations and favorable tolerability profile. Nabriva also
intends to further pursue the development of lefamulin for
additional indications, including the treatment of acute bacterial
skin and skin structure infections, and is developing a formulation
of lefamulin appropriate for pediatric use.
Nabriva owns exclusive, worldwide rights to lefamulin, which is
protected by composition of matter patents issued in the United
States, Europe and Japan.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Nabriva, including but not limited to
statements about the composition of its Supervisory Board,
development of Nabriva’s product candidates, such as plans for the
design, conduct and timelines of Phase 3 clinical trials of
lefamulin for CABP, the clinical utility of lefamulin for CABP and
Nabriva’s plans for filing of regulatory approvals and efforts to
bring lefamulin to market, the development of lefamulin for
additional indications, the development of additional formulations
of lefamulin, plans to pursue research and development of other
product candidates and other statements containing the words
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,”
“plan,” “predict,” “project,” “target,” “potential,” “likely,”
“will,” “would,” “could,” “should,” “continue,” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including: the uncertainties inherent in the initiation
and conduct of clinical trials, availability and timing of data
from clinical trials, whether results of early clinical trials or
trials in different disease indications will be indicative of the
results of ongoing or future trials, uncertainties associated with
regulatory review of clinical trials and applications for marketing
approvals, the availability or commercial potential of product
candidates including lefamulin for use as a first-line empiric
monotherapy for the treatment of moderate to severe CABP, the
sufficiency of cash resources and need for additional financing and
such other important factors as are set forth under the caption
"Risk Factors" in Nabriva’s annual report on Form 20-F as filed
with the United States Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent Nabriva’s views as of the date of this release.
Nabriva anticipates that subsequent events and developments will
cause its views to change. However, while Nabriva may elect to
update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Nabriva’s views as of any date subsequent to the date
of this release.
Contact:
Will Sargent
Nabriva Therapeutics AG
William.Sargent@nabriva.com
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Sep 2023 to Sep 2024